Population
37 immunodeficient patients with vaccine-associated paralytic poliomyelitis reported in the United States…
Design
Cohort
Follow-up
up to 10 years
Authors
Loading...
Prolonged excretion in iVAPP may pose limited reintroduction risk; leaves open surveillance needs in immunodeficient populations.
Despite high prevalence of poliovaccine virus persistence among patients with iVAPP, they are an unlikely source of poliovirus reintroduction due to rarity, high fatality rate, and possible spontaneous clearance.
Khetsuriani et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: